About: http://data.cimple.eu/news-article/dea6854ed8579374426e34743f38f9b33ba1f748351f28ea78859d0b

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: http://data.cimple.eu/news-article/dea6854ed8579374426e34743f38f9b33ba1f748351f28ea78859d0b Goto Sponge NotDistinct Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

Attributes	Values
rdf:type	schema:NewsArticle
schema:articleBody	French pharma giant Sanofi said Monday it will buy US group Principia Biopharma for $3.7 billion in a deal that will boost its research and development into auto-immune and allergic diseases. Sanofi boss Paul Hudson said the deal was an "important step" and would help the company's development of the most promising medical treatments. The deal, expected to be completed later this year, will see Sanofi "acquire all of the outstanding shares of Principia for $100 per share in cash, which represents an aggregate equity value of approximately $3.68 billion", Sanofi said in a statement. Sanofi has been cooperating with San Francisco-based Principia since 2017, securing an exclusive global licence to develop and market its BTK'168 drug for treating multiple sclerosis and other central nervous system illnesses. "Full ownership... removes complexities for this priority development programme and simplifies future commercialisation," Hudson said. Beyond diseases of the nervous system, Principia hopes to develop "a whole portfolio" of similar drugs that could target different organ systems in patients suffering from "immune-mediated" diseases, chief executive Martin Babler said. Principia Biopharma specialises in the development of treatments to control and reduce inflammation caused by auto-immune diseases -- where the body's own defences attack healthy tissues. BTK'168 is currently in Phase III clinical trials, the last stage before the company can apply for approval for its use. Principia Biopharma is also developing other treatments, notably rilzabrutinib for pemphigus, a rare and painful chronic condition causing blisters and sores, which is also in Phase III trials. Sanofi R&D head Dr. John Reed said both compounds had the potential to be used in multiple treatments. Earlier this year, Sanofi acquired another US biotech company Synthorx, a specialist in cancer treatments, for $2.5 billion. Shortly after, it sold its holding in US biotech Regeneron for some $12 billion. Sanofi is separately involved in efforts to develop a coronavirus vaccine and appears to be among the frontrunners to produce one. sbo/tq/eb/bmm/pma sbo/tgb/wdb
schema:headline	France's Sanofi to buy US group Principia Biopharma for $3.68 bn
schema:mentions	Research and development Private equity Multiple sclerosis Central nervous system Hudson River Severe acute respiratory syndrome-related coronavirus Autoimmune disease Inflammation USA Gymnastics Glenn L. Martin Company Cancer France Vaccine Praetorium Multiple treatments Pemphigus John S. Reed Bruton's tyrosine kinase Sanofi Mark Roebuck
schema:author	http://data.cimple.eu/organization/1f0054d541e000623a2c1e561a247c073ef6328e8be9ffafda7b3fcd
schema:datePublished	2020-08-17 (xsd:date)
http://data.cimple...sPoliticalLeaning	other political leaning
http://data.cimple...logy#hasSentiment	positive sentiment
http://data.cimple...readability_score	80 (xsd:integer)
http://data.cimple...tology#hasEmotion	happiness

Faceted Search & Find service v1.16.115 as of Oct 09 2023

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 11 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software